

Table 9.27
All Lymphoid Neoplasms With Detailed Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2005-2011

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)		Percent (95% C.I.)		Percent (95% C.I.)	
Lymphoid Neoplasm	76,981	69.5 (69.0 , 69.9)	90.2 (89.1 , 91.2)		79.2 (78.7 , 79.7)		58.7 (57.9 , 59.4)	
1 Hodgkin Lymphoma	6,796	86.9 (85.9 , 87.8)	96.9 (95.4 , 97.9)		91.5 (90.5 , 92.4)		54.3 (50.1 , 58.3)	
1(a) Classical Hodgkin lymphoma	6,566	86.7 (85.6 , 87.6)	96.8 (95.3 , 97.9)		91.5 (90.5 , 92.4)		53.1 (48.9 , 57.1)	
1(a)1. Lymphocyte-rich/mixed cellularity/ lymphocyte-depleted	885	78.3 (74.7 , 81.4)	96.7 (87.0 , 99.2)		87.5 (84.0 , 90.3)		54.4 (46.2 , 61.9)	
1(a)1.1 Lymphocyte-rich	193	87.9 (80.0 , 92.8)	- (- , -)		94.2 (87.5 , 97.3)		68.7 (47.7 , 82.6)	
1(a)1.2 Mixed cellularity	610	77.8 (73.5 , 81.5)	95.2 (81.9 , 98.8)		86.0 (81.6 , 89.5)		55.2 (45.0 , 64.3)	
1(a)1.3 Lymphocyte-depleted	82	58.6 (45.1 , 69.9)	- (- , -)		78.0 (58.8 , 89.0)		28.5 (11.8 , 47.8)	
1(a)2. Nodular sclerosis	4,303	91.3 (90.2 , 92.2)	96.7 (94.9 , 97.9)		93.8 (92.6 , 94.7)		58.1 (51.1 , 64.5)	
1(a)3. Classical Hodgkin lymphoma, NOS ^c	1,378	77.0 (74.2 , 79.6)	97.4 (92.0 , 99.2)		85.6 (82.6 , 88.1)		44.9 (37.7 , 51.9)	
1(b) Nodular lymphocyte predominant Hodgkin Lymphoma	230	92.9 (86.1 , 96.5)	- (- , -)		92.8 (85.4 , 96.5)		82.4 (28.9 , 97.0)	
2 Non-Hodgkin lymphoma	68,074	68.3 (67.8 , 68.8)	88.1 (86.7 , 89.3)		77.3 (76.7 , 77.9)		59.5 (58.7 , 60.2)	
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	40	45.0 (23.8 , 64.2)	- (- , -)		- (- , -)		- (- , -)	
4 Lymphoid neoplasm, NOS ^c	2,071	49.1 (46.3 , 51.8)	89.6 (71.0 , 96.5)		66.3 (61.8 , 70.3)		39.9 (36.3 , 43.4)	

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified.

- Statistic not displayed due to less than 25 cases.